Medical hypothesis discovery and innovation in ophthalmology

Lee PN, Hamling JS. Environmental tobacco smoke exposure and risk of breast cancer in nonsmoking women. An updated review and meta-analysis. Inhalation toxicology. 2016;28(10):431-54. PMID: 27541291

Holdenrieder S. Biomarkers along the continuum of care in lung cancer. Scandinavian journal of clinical and laboratory investigation. 2016;76(sup245):S40-S5. PMID: 27542002

Papadopoulou E, Tsoulos N, Tsirigoti A, Apessos A, Agiannitopoulos K, Metaxa-Mariatou V, et al. Determination of EGFR and KRAS mutational status in Greek non-small-cell lung cancer patients. Oncology letters. 2015;10(4):2176-84. PMID: 26622815

Milovancev A, Stojsic V, Zaric B, Kovacevic T, Sarcev T, Perin B, et al. EGFR-TKIs in adjuvant treatment of lung cancer: to give or not to give? OncoTargets and therapy. 2015;8:2915-21. PMID: 26508876

Lampaki S, Lazaridis G, Zarogoulidis K, Kioumis I, Papaiwannou A, Tsirgogianni K, et al. Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer. Journal of Cancer. 2015;6(6):568-74. PMID: 26000049

Domvri K, Zarogoulidis P, Darwiche K, Browning RF, Li Q, Turner JF, et al. Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy. Journal of Cancer. 2013;4(9):736-54. PMID: 24312144

Zarogoulidis K, Zarogoulidis P, Darwiche K, Boutsikou E, Machairiotis N, Tsakiridis K, et al. Treatment of non-small cell lung cancer (NSCLC). Journal of thoracic disease. 2013;5 Suppl 4:S389-96. PMID: 24102012

Boutsikou E, Kontakiotis T, Zarogoulidis P, Darwiche K, Eleptheriadou E, Porpodis K, et al. Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer. OncoTargets and therapy. 2013;6:125-34. PMID: 23467839

Xu Y, Ding VW, Zhang H, Zhang X, Jablons D, He B. Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far. Therapeutics and clinical risk management. 2016;12:807-16. PMID: 27307741

Schwitter M, Rodriguez R, Schneider T, Kluckert T, Brutsche M, Fruh M. Epidermal growth factor receptor mutation in a patient with squamous cell carcinoma of the lung: who should be tested? Case reports in oncology. 2013;6(2):263-8. PMID: 23741221

Stefano A, Russo G, Ippolito M, Cosentino S, Mure G, Baldari S, et al. Evaluation of erlotinib treatment response in non-small cell lung cancer using metabolic and anatomic criteria. The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine. 2016;60(3):264-73. PMID: 27463889

He X, Zhang Y, Ma Y, Zhou T, Zhang J, Hong S, et al. Optimal tumor shrinkage predicts long-term outcome in advanced nonsmall cell lung cancer (NSCLC) treated with target therapy: Result from 3 clinical trials of advanced NSCLC by 1 institution. Medicine. 2016;95(31):e4176. PMID: 27495021

Mattonen SA, Ward AD, Palma DA. Pulmonary imaging after stereotactic radiotherapy-does RECIST still apply? The British journal of radiology. 2016;89(1065):20160113. PMID: 27245137

Sun JM, Ahn MJ, Choi YL, Ahn JS, Park K. Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors. Lung cancer. 2013;82(2):294-8. PMID: 24035188

Surriga O, Rajasekhar VK, Ambrosini G, Dogan Y, Huang R, Schwartz GK. Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model. Molecular cancer therapeutics. 2013;12(12):2817-26. PMID: 24140933

Tseng JS, Su KY, Yang TY, Chen KC, Hsu KH, Chen HY, et al. The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M. Oncotarget. 2016. PMID: 27384480

Isobe K, Hata Y, Tochigi N, Kaburaki K, Kobayashi H, Makino T, et al. Usefulness of nanofluidic digital PCR arrays to quantify T790M mutation in EGFR-mutant lung adenocarcinoma. Cancer genomics & proteomics. 2015;12(1):31-7. PMID: 25560642

Inoue M, Watanabe Y, Yamane S, Kobayashi S, Arakawa A, Tsukahara T, et al. Choroidal metastasis with adenocarcinoma of the lung treated with gefitinib. European journal of ophthalmology. 2010;20(5):963-5. PMID: 20383850

Economou MA. Uveal melanoma and macular degeneration: molecular biology and potential therapeutic applications. Acta ophthalmologica. 2008;86(8):930-1. PMID: 19086934

All-Ericsson C, Girnita L, Seregard S, Bartolazzi A, Jager MJ, Larsson O. Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Investigative ophthalmology & visual science. 2002;43(1):1-8. PMID: 11773005

Li SH, Hsieh MH, Fang YF. Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series. Medicine. 2015;94(41):e1739. PMID: 26469914

Yu HA, Tian SK, Drilon AE, Borsu L, Riely GJ, Arcila ME, et al. Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain. JAMA oncology. 2015;1(7):982-4. PMID: 26181354

Hasegawa T, Sawa T, Futamura Y, Horiba A, Ishiguro T, Marui T, et al. Feasibility of Rebiopsy in Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors. Internal medicine. 2015;54(16):1977-80. PMID: 26278287

Hata A, Katakami N, Yoshioka H, Kaji R, Masago K, Fujita S, et al. Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015;10(11):1553-9. PMID: 26309190

Jekunen AP. Role of rebiopsy in relapsed non-small cell lung cancer for directing oncology treatments. Journal of oncology. 2015;2015:809835. PMID: 25699082

Bosc C, Ferretti GR, Cadranel J, Audigier-Valette C, Besse B,

Barlesi F, et al. Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC. Targeted oncology. 2015;10(2):247-53. PMID: 25119973

Moldvay J, Papay J, Kovalszky I, Balazs G, Puskas R, Losonczy G. [Gefitinib treatment in lung cancer -- rebiopsy, retreatment, remission]. Magyar onkologia. 2014;58(2):133-7. PMID: 25010762

Kuiper JL, Heideman DA, Thunnissen E, Paul MA, van Wijk AW, Postmus PE, et al. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. Lung cancer. 2014;85(1):19-24. PMID: 24768581

Hata A, Katakami N, Yoshioka H, Takeshita J, Tanaka K, Nanjo S, et al. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations. Cancer. 2013;119(24):4325-32. PMID: 24105277

Arcila ME, Oxnard GR, Nafa K, Riely GJ, Solomon SB, Zakowski MF, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011;17(5):1169-80. PMID: 21248300